script.reportAU
Register
← The record

Goserelin Acetate

Recommended OncologyAuthority Required

Hormone dependent early breast cancer in peri or pre-menopausal women as an alternative to adjuvant chemotherapy or oophorectomy.

1
Submissions
2009–09
On the record
—
ICER range
Cost-min
Cost basis

Access path

1 submission · public record
  1. Nov 2009
    Recommended

    vs chemotherapy (CMF, anthracycline-based regimens) and…

  2. PBS listing · Authority Required
RecommendedDeferredNot recommended

Cost-effectiveness

Cost-minimisation analysis; no ICER calculated. Submission presented cost analysis showing cost saving versus chemotherapy and nominal incremental cost versus oophorectomy.

The PBAC noted that the main translational issue was that the majority of the clinical data compares goserelin to the chemotherapy regimen CMF, which is no longer used in clinical practice. PBAC · 2009

Decision context

PopulationPeri or pre-menopausal women with hormone receptor positive early breast cancer (stage III or IV)

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Nov 2009 Recommended chemotherapy (CMF, anthracycline-based regimens) and oophorectomy — Meta-analysis